Q32 Bio Inc (QTTB)
NASDAQ:QTTB
Want to see QTTB full AI Analyst Report?
Top Page
Q32 Bio
(NASDAQ:QTTB)
Select Model
Select Model
Rating:69Neutral
Price Target:
$14.00
▲(139.32% Upside)
Action:Reiterated
Date:06/17/26
The score is driven by strong technical momentum and attractive P/E valuation, partially offset by weak cash-flow fundamentals (persistent cash burn) that increase financing risk; recent capital-raise events improve liquidity but add dilution considerations.
Positive Factors
Improving balance sheet and lower leverage
Leverage has materially improved to a manageable ~0.24 D/E, supported by a meaningful equity base (~$46.3M) and assets (~$63.7M). This stronger capital structure reduces near-term refinancing pressure and gives the company structural flexibility to fund clinical programs over the next several quarters.
Negative Factors
Negative operating and free cash flow
Persistent negative OCF and FCF (~-$27.4M TTM) mean the business is not yet self-funding and will likely need external capital to sustain clinical development. This structural cash burn elevates financing and execution risk over the next 2–6 months absent sustained cash generation or material non-dilutive funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving balance sheet and lower leverage
Leverage has materially improved to a manageable ~0.24 D/E, supported by a meaningful equity base (~$46.3M) and assets (~$63.7M). This stronger capital structure reduces near-term refinancing pressure and gives the company structural flexibility to fund clinical programs over the next several quarters.
Read all positive factors
Q32 Bio (QTTB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$201.78M
Dividend YieldN/A
Average Volume (3M)1.18M
Price to Earnings (P/E)5.0
Beta (1Y)0.46
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.68
Shares Outstanding16,956,415
10 Day Avg. Volume555,650
30 Day Avg. Volume1,180,498
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.22
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit2.35
Enterprise Value/Ebitda5.65
Forecast
1Y Price Target
$12.33Price Target Upside110.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.83
Revenue Forecast (FY)N/A
Q32 Bio Business Overview & Revenue Model
Company Description
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disord...
How the Company Makes Money
null...
Q32 Bio Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
72
Positive
Cash Flow
36
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.74M | 53.74M | 0.00 | -6.65M | 6.65M | 33.97M |
| Gross Profit | 53.38M | 53.35M | -487.00K | -6.65M | 6.65M | 24.43M |
| EBITDA | 22.15M | 17.29M | -45.30M | -47.76M | -38.85M | -86.22M |
| Net Income | 33.24M | 29.82M | -47.73M | -53.74M | -42.81M | -95.76M |
Balance Sheet | ||||||
| Total Assets | 63.67M | 61.78M | 92.33M | 47.06M | 61.77M | 211.72M |
| Cash, Cash Equivalents and Short-Term Investments | 50.75M | 48.30M | 77.97M | 25.62M | 43.89M | 155.87M |
| Total Debt | 13.65M | 15.34M | 18.90M | 50.84M | 44.73M | 23.93M |
| Total Liabilities | 17.36M | 19.76M | 86.66M | 229.98M | 192.49M | 42.07M |
| Stockholders Equity | 46.31M | 42.01M | 5.67M | -182.92M | 177.98M | 169.65M |
Cash Flow | ||||||
| Free Cash Flow | -27.40M | -33.54M | -67.79M | -18.68M | -13.44M | -112.15M |
| Operating Cash Flow | -27.40M | -33.54M | -67.72M | -18.68M | -10.96M | -109.75M |
| Investing Cash Flow | 7.00M | 7.00M | 19.93M | -5.00K | -2.47M | -50.79M |
| Financing Cash Flow | 5.67M | -3.13M | 95.14M | 406.00K | 30.07M | 52.17M |
Q32 Bio Technical Analysis
Positive
5.85
Price Trends
8.02
Positive
6.62
Positive
4.69
Positive
Market Momentum
1.46
Positive
57.56
Neutral
42.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QTTB, the sentiment is Positive. The current price of 5.85 is below the 20-day moving average (MA) of 11.44, below the 50-day MA of 8.02, and above the 200-day MA of 4.69, indicating a bullish trend. The MACD of 1.46 indicates Positive momentum. The RSI at 57.56 is Neutral, neither overbought nor oversold. The STOCH value of 42.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QTTB.
Q32 Bio Risk Analysis
Q32 Bio disclosed 84 risk factors in its most recent earnings report. Q32 Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Q32 Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $201.78M | 5.05 | 230.68% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $53.30M | -1.59 | -346.03% | ― | ― | 28.53% | |
49 Neutral | $29.02M | -0.56 | -503.79% | ― | ― | 82.28% | |
45 Neutral | $36.83M | -4.14 | -12.66% | ― | ― | 43.67% | |
45 Neutral | $11.93M | -0.58 | -526.36% | ― | ― | 16.33% | |
42 Neutral | $18.21M | -0.31 | -309.60% | ― | ― | 65.65% |
* Healthcare Sector Average
QTTB
Q32 Bio
11.90
10.35
667.74%
TPST
Tempest Therapeutics
1.23
-5.55
-81.86%
PDSB
PDS Biotechnology
0.96
-0.67
-41.05%
GRCE
Grace Therapeutics
2.38
-0.62
-20.67%
CALC
CalciMedica
0.76
-0.88
-53.96%
SNTI
Senti Biosciences
0.93
-1.20
-56.29%
Q32 Bio Corporate Events
Executive/Board ChangesShareholder Meetings
Q32 Bio Shareholders Back Directors, Auditor and Executive Pay
Positive
Jun 16, 2026
At Q32 Bio Inc.’s 2026 Annual Meeting of Stockholders, held with approximately 75.71% of eligible common shares represented, investors elected Class II directors Kathleen LaPorte, Jodie Morrison and Arthur Tzianabos, Ph.D., to three-year ter...
Business Operations and StrategyPrivate Placements and Financing
Q32 Bio Raises $55 Million in Private Placement
Positive
May 27, 2026
On May 26, 2026, Q32 Bio Inc. signed a securities purchase agreement with institutional and other accredited investors for a private placement of 6,725,000 common shares at $8.00 each and pre-funded warrants for 150,000 additional shares, for expe...
Private Placements and FinancingRegulatory Filings and Compliance
Q32 Bio Expands ATM Offering With New $75M Prospectus
Neutral
Apr 24, 2026
On March 27, 2026, Q32 Bio Inc. entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald Co., enabling at-the-market sales of its common stock under a prospectus supplement for up to $14.2 million. Having now sold the full...
Business Operations and StrategyPrivate Placements and Financing
Q32 Bio Launches Flexible $14.2 Million ATM Program
Positive
Mar 27, 2026
On March 27, 2026, Q32 Bio entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald to establish an at-the-market equity program for its common stock. The arrangement allows the company, at its discretion, to sell up to $14...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.